PURE Bioscience (PURE) Reports $144M Deal and Exclusive Middle East Distribution Channel for IV-7 Water Treatment

QualityStocks would like to highlight PURE Bioscience (NASDAQ: PURE). The company develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection.

In the company’s news yesterday,

PURE Bioscience conducted a quarterly investor call, in which they disclosed a major contractual agreement between its sales agent, Richmont Sciences, and Dubai-based High Scope Trading LLC.

The commitment by High Scope is projected to exceed $144M in orders over 10 years and should initially consist primarily of the revolutionary IV-7 Water Treatment™ product, which utilizes PURE’s SDC technology (ionic silver stabilized in citric acid).

Only two ounces of IV-7 Water Treatment per 200 gallons can produce safe, drinkable water in minutes, with no odor or taste; substantially reducing gastrointestinal illness rates and bearing no toxic or environmentally pollutive byproducts.

Management at PURE is projecting that High Scope will deal directly with the Company in future and hence is reassigning the agreement to PURE, after which time Richmont will function as sales agent on the PURE/High Scope transactions, as well as the sanitizer and commercial disinfectant programs.

President and CEO of PURE, Michael L. Krall, said this deal opens the door to not only the ongoing revenue, but also exclusive distribution in the Middle East.

First year minimum from High Scope is $9M, with annual minimums increasing to over $21M by year ten, and while not guaranteed, the figures represent realistic projections and accompany exclusive access to a key market.

Krall noted the buzz generated by the IV-7 Water Treatment program and foresees amazing growth potential from this segment over the next several years.

Chairman of Richmont, John Rochon, explained Richmont’s multi-faceted approach to global distribution of the lifesaving IV-7 product and cited the significance of progress in the Middle East as an important step towards the goal of maximizing the quality of life impact.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.